Zynerba Pharmaceuticals, Inc. (ZYNE) Social Stream
Zynerba Pharmaceuticals Inc (ZYNE) Price Targets From Analysts
Use the tables below to see what analysts covering Zynerba Pharmaceuticals Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
ZYNE's average price target has moved down $1.19 over the prior 43 weeks.
Over the past 47 weeks, ZYNE's average upside potential has been 91.78%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
ZYNE Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 59 days, ZYNE's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- To contextualize these metrics, consider that out of all US stocks, Zynerba Pharmaceuticals Inc's average analyst price target is greater than 26.23% of them.
- ZYNE has a greater upside potential (average analyst target price relative to current price) than 450.95% of all US stocks.
- Zynerba Pharmaceuticals Inc's variance in analysts' estimates is lower than -325.37% of all US stocks.
- To contextualize these metrics, consider that out of stocks in the micro market cap category, Zynerba Pharmaceuticals Inc's number of analysts covering the stock is greater than 403.12% of them.
Make investment decisions regarding ZYNE using the data that counts. Try POWR Ratings for free.